CLAIMS

1. Use of an IL-33 axis binding antagonist in the manufacture of a medicament for treating or preventing acute respiratory distress syndrome (ARDS) in a patient at risk thereof, wherein an effective amount of the IL-33 axis binding antagonist is to be administered to the patient.
2. The use of claim 1, wherein the medicament is capable of preventing ARDS in said patient.
3. The use of any preceding claim, wherein the patient has mild, moderate, or moderate-to-severe hypoxemia.
4. Use of an IL-33 axis binding antagonist in the manufacture of a medicament for treating hypoxemia in a patient, wherein an effective amount of the IL-33 axis binding antagonist is to be administered to the patient.
5. The use of claim 4, wherein the hypoxemia is mild, moderate, or moderate-to-severe hypoxemia.
6. The use according to any preceding claim, wherein the patient has hypercarbia.
7. The use of any preceding claim, wherein the patient has excessive pulmonary inflammation.
8. The use according to any preceding claim, wherein the medicament is capable of reducing or inhibiting inflammation in the lung.
9. Use of an IL-33 axis binding antagonist in the manufacture of a medicament for treating excessive pulmonary inflammation in a subject, wherein an effective amount of the IL-33 axis binding antagonist is to be administered to the patient.
10. The use of claim 9, wherein the patient has, or is at risk of developing, ARDS.
11. The use of any of claims 7 to 10, wherein the excessive pulmonary inflammation is caused by pneumonia (viral or bacterial) or severe flu, sepsis, a severe chest injury (e.g. major trauma and/or multiple fractures), aspiration of gastric contents (e.g. accidentally inhaling vomit), smoke or toxic chemicals inhalation, near drowning, pulmonary contusion, fat emboli, pulmonary vasculitis, non-cardiogenic shock or an adverse reaction to a blood transfusion.
12. The use of any preceding claim, wherein the patient has pneumonia.
13. The use of claim 12, wherein the pneumonia is viral pneumonia.
14. The use according to any preceding claim, wherein the patient has coronavirus 2 (SARS-CoV-2) infection.
15. The use according to claim 14, wherein the ARDS, hypoxemia or excessive pulmonary inflammation is induced by SARS-CoV-2.

16. The use according to any preceding claim, wherein the patient's partial pressure of oxygen is less than 79 mm HG.

17. The use according to any preceding claim, wherein the patient's partial pressure of oxygen is between 60 and 79 mm HG, inclusive.

18. The use according to any of claims 1 to 15, wherein the patient's partial pressure of oxygen is less than 60 mm HG.

19. The use according to any preceding claim, wherein the patient is not or has not yet received mechanical ventilation.

20. The use according to any preceding claim, wherein the IL-33 axis binding antagonist is an anti-IL-33 antagonist, an anti-ST2 antagonist or an IL1-RAcP antagonist.

21. The use of claim 20, wherein the antagonist is an antibody, or antigen binding fragment thereof.

22. The use of claim 21, wherein the antibody is an anti-IL-33 antibody, or antigen binding fragment thereof.

23. The use according to claim 22, wherein the anti-IL33 antibody, or antigen binding fragment thereof, comprising a VHCDR1 having the sequence of SEQ ID NO: 37, a VHCDR2 having the sequence of SEQ ID NO: 38, a VHCDR3 having the sequence of SEQ ID NO: 39, a VLCDR1 having the sequence of SEQ ID NO: 40, a VLCDR2 having the sequence of SEQ ID NO: 41, and a VLCDR3 having the sequence of SEQ ID NO: 42.

24. Use of an anti-IL33 antibody, or antigen binding fragment thereof in the manufacture of a medicament for treating or preventing coronavirus disease 2019 (COVID-19) in a patient, wherein an effective amount of the anti-IL33 antibody, or antigen binding fragment thereof is to be administered to the patient, wherein the anti-IL33 antibody, or antigen binding fragment thereof, comprising a VHCDR1 having the sequence of SEQ ID NO: 37, a VHCDR2 having the sequence of SEQ ID NO: 38, a VHCDR3 having the sequence of SEQ ID NO: 39, a VLCDR1 having the sequence of SEQ ID NO: 40, a VLCDR2 having the sequence of SEQ ID NO: 41, and a VLCDR3 having the sequence of SEQ ID NO: 42.

25. Use of the anti-IL33 antibody, or antigen binding fragment thereof, defined in claim 24 in the manufacture of a medicament for preventing or treating acute respiratory insufficiency induced by coronavirus 2 (SARS-CoV-2) infection in a patient, wherein an effective amount of the anti-IL33 antibody, or antigen binding fragment thereof is to be administered to the patient.

26. Use of the anti-IL33 antibody, or antigen binding fragment thereof, defined in claim 24 in the manufacture of a medicament for preventing or treating acute respiratory distress syndrome (ARDS) induced by coronavirus 2 (SARS-CoV-2) infection in a patient, wherein an effective amount of the anti-IL33 antibody, or antigen binding fragment thereof is to be administered to the patient.

27. Use of the anti-IL33 antibody, or antigen binding fragment thereof, defined in claim 24 in the manufacture of a medicament for treating or preventing excessive pulmonary inflammation in a patient infected by SARS-CoV-2 or a patient with COVID-19, an effective amount of the anti-IL33 antibody, or antigen binding fragment thereof is to be administered to the patient.